Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Common Equity (2016 - 2025)

AC Immune (ACIU) has disclosed Common Equity for 9 consecutive years, with $128.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Common Equity fell 29.23% to $128.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $128.2 million, a 29.23% decrease, with the full-year FY2024 number at $128.2 million, down 28.35% from a year prior.
  • Common Equity was $128.2 million for Q4 2024 at AC Immune, down from $181.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $251.6 million in Q4 2021 to a low of $128.2 million in Q4 2024.
  • A 5-year average of $194.9 million and a median of $181.1 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: rose 5.55% in 2021, then tumbled 30.27% in 2022.
  • AC Immune's Common Equity stood at $238.4 million in 2020, then rose by 5.55% to $251.6 million in 2021, then tumbled by 30.27% to $175.4 million in 2022, then rose by 3.24% to $181.1 million in 2023, then fell by 29.23% to $128.2 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Common Equity are $128.2 million (Q4 2024), $181.1 million (Q4 2023), and $175.4 million (Q4 2022).